NeoGenomics, Inc. (NEO) Covered Calls

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in oncologic genetics testing and information services. The company provides advanced diagnostic, prognostic, and predictive testing tools to oncologists, pathologists, hospital systems, and pharmaceutical firms. Operating through clinical and pharma services segments, it integrates cytogenetics, flow cytometry, and molecular analysis to guide personalized cancer care and support oncology drug development.

You can sell covered calls on NeoGenomics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for NEO (prices last updated Mon 2:15 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

NeoGenomics, Inc. operates as a specialized network of oncology laboratories, providing high-complexity diagnostic testing services. The company plays a critical role in cancer treatment pathways by analyzing tissue, blood, and bone marrow samples. Its comprehensive test menu covers diagnostic, prognostic, and predictive evaluations to help clinicians determine the precise nature and progression of a patient's cancer.

The core clinical business relies on integrating multiple advanced medical laboratory tech platforms. These methodologies include cytogenetics, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, and next-generation molecular sequencing. By unifying these diverse diagnostic workflows under one operational umbrella, the firm delivers fast, comprehensive diagnostic reports that allow oncologists to design highly tailored, personalized therapies.

Beyond direct clinical testing for medical providers, the company runs a robust pharmaceutical services business. This business division supports biotech and pharmaceutical developers throughout the clinical trial process. The laboratory network provides custom assay development, patient screening protocols, and biomaterial tracking from early discovery phases through global regulatory approvals, ensuring new targeted therapies can move efficiently to the public market.

Competition

The oncology diagnostics industry is highly technical and contains both broad clinical laboratory networks and niche molecular testing specialists. Important industry participants include:

1. Quest Diagnostics runs a massive, centralized diagnostic testing network across the country, leveraging immense scale to compete on routine oncology screens and specialty provider access.
2. Labcorp operates an expansive clinical network, utilizing its deep infrastructure and comprehensive testing menu to secure major health system partnerships.
3. Natera focuses heavily on cell-free DNA testing technologies, competing directly in the rapidly expanding space of minimal residual disease testing and cancer recurrence monitoring.

The company maintains its distinct edge over diversified diagnostic giants by operating as a pure-play cancer testing network. Unlike general laboratories that handle broad medical testing categories, every technician, pathologist, and customer support portal within this infrastructure is specifically aligned with oncologic care, creating highly specialized service standards.

Strategic Outlook and Innovation

The forward strategic roadmap prioritizes expanding next-generation sequencing panels and advanced liquid biopsy offerings. These non-invasive blood tests allow clinicians to track real-time tumor mutations and molecular changes without putting patients through repeated surgical procedures. Innovation efforts center on perfecting minimal residual disease assays to detect ultra-low concentrations of circulating tumor DNA before visible tumors reappear.

Operational strategy involves deepening information service capabilities by leveraging a proprietary, de-identified clinical genomic database. This extensive registry of historical cancer profiles serves as a valuable resource for research institutions studying cancer patterns and drug responses. By turning diagnostic test results into clean, actionable analytical insights, the company builds stable, long-term relationships across the healthcare ecosystem.

Want more examples? NEM Covered Calls | NEOG Covered Calls